Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression
暂无分享,去创建一个
Jeremy J. W. Chen | Yih-Leong Chang | J. Shih | Pan‐Chyr Yang | Chong-Jen Yu | Chao-Chi Ho | Chung-Yu Chen | Ying-Yin Chen | Kuan-Yu Chen
[1] B. Jiang,et al. B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway , 2016, Tumor Biology.
[2] Sandra Zazo,et al. Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer , 2015, BMC Pulmonary Medicine.
[3] Shan Lu,et al. The expression of astrocyte elevated gene‐1 in human non‐small‐cell lung cancer and its relationship with postoperative chemotherapy and radiotherapy , 2015, Histopathology.
[4] Hui Zhang,et al. RNA Interference-Mediated Knockdown of Astrocyte Elevated Gene-1 Inhibits Growth, Induces Apoptosis, and Increases the Chemosensitivity to 5-Fluorouracil in Renal Cancer Caki-1 Cells , 2014, Molecules and cells.
[5] R. Rosell,et al. Predicting resistance by selection of signaling pathways. , 2014, Translational lung cancer research.
[6] P. Krawczyk,et al. Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients , 2014, Journal of Cancer Research and Clinical Oncology.
[7] Leping Li,et al. Progress of cancer research on astrocyte elevated gene-1/Metadherin (Review) , 2014, Oncology letters.
[8] B. Zhu,et al. Knockdown of astrocyte elevated gene-1 (AEG-1) in cervical cancer cells decreases their invasiveness, epithelial to mesenchymal transition, and chemoresistance , 2014, Cell cycle.
[9] Haiquan Chen,et al. The pemetrexed-containing treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis , 2014, BMC Cancer.
[10] Yu Liu,et al. Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis , 2013, Cancer Chemotherapy and Pharmacology.
[11] Ting Wang,et al. Association between TYMS Expression and Efficacy of Pemetrexed–Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis , 2013, PloS one.
[12] C. Gridelli,et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Eun Joo Lee,et al. Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin. , 2013, Lung cancer.
[14] Tuan S. Nguyen,et al. Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non–Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[15] A. Buqué,et al. Thymidylate Synthase Expression Determines Pemetrexed Targets and Resistance Development in Tumour Cells , 2013, PloS one.
[16] T. Oguri,et al. Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma. , 2013, Anticancer Research.
[17] J. Sculier. Nonsmall cell lung cancer , 2013, European Respiratory Review.
[18] Minwen Ha,et al. Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC , 2013, Journal of Biomedical Science.
[19] Lian-tang Wang,et al. AEG-1 expression characteristics in human non-small cell lung cancer and its relationship with apoptosis , 2013, Medical Oncology.
[20] F. Hirsch,et al. Significance of Folate Receptor Alpha and Thymidylate Synthase Protein Expression in Patients with Non–Small-Cell Lung Cancer Treated with Pemetrexed , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[21] J. Luketich,et al. The Platinum-Based Treatments for Advanced Non-small Cell Lung Cancer: Is Excision Repair Cross-Complementation Group 1 Low/Negative Expression Better Than Its High/Positive Expression? A Metaanalysis , 2010 .
[22] M. Fukuoka,et al. Identification of thymidylate synthase as a potential therapeutic target for lung cancer , 2010, British Journal of Cancer.
[23] P. Fisher,et al. Molecular mechanism of chemoresistance by astrocyte elevated gene-1. , 2010, Cancer research.
[24] Thomas J. Smith,et al. 美国临床肿瘤学会Ⅳ期非小细胞肺癌化疗的临床实践指南更新 , 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.
[25] Libing Song,et al. Over‐expression of AEG‐1 significantly associates with tumour aggressiveness and poor prognosis in human non‐small cell lung cancer , 2009, The Journal of pathology.
[26] K. Krejcy,et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study , 2009, The Lancet.
[27] Yibin Kang,et al. The Multifaceted Role of MTDH/AEG-1 in Cancer Progression , 2009, Clinical Cancer Research.
[28] Talitha L Forcier,et al. Identification of genes conferring resistance to 5-fluorouracil , 2009, Proceedings of the National Academy of Sciences.
[29] Xianrang Song,et al. Knockdown of astrocyte elevated gene-1 inhibits proliferation and enhancing chemo-sensitivity to cisplatin or doxorubicin in neuroblastoma cells , 2009, Journal of experimental & clinical cancer research : CR.
[30] Michael Reiss,et al. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. , 2009, Cancer cell.
[31] Johan Vansteenkiste,et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Dong-Chul Kang,et al. Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration. , 2007, Pharmacology & therapeutics.
[33] P. Fisher,et al. Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc , 2006, Proceedings of the National Academy of Sciences.
[34] G. Scagliotti,et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase , 2006, Cancer.
[35] Miklos Pless,et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] R M Schultz,et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. , 1997, Cancer research.
[37] A. Jemal,et al. Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.
[38] S. Temin,et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2016, Journal of oncology practice / American Society of Clinical Oncology.
[39] S. Temin,et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2016, Journal of oncology practice.
[40] K. Thiel,et al. Drug resistance mediated by AEG-1/MTDH/LYRIC. , 2013, Advances in cancer research.
[41] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[42] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.